Vanderbilt Center for Cognitive Medicine Archive — Page 1 of 1

(iStock)
July 3, 2026

Vanderbilt Center for Cognitive Medicine seeks participants for trial evaluating Alzheimer’s disease-related psychosis treatment

The ADEPT-4 study evaluates KarXT, an oral medication that may reduce hallucinations and delusions.

Smiling man in a blue shirt photographed outdoors at sunset, with water and a railing in the background.
March 18, 2026

Vanderbilt Center for Cognitive Medicine enrolls first Down syndrome participant for Alzheimer’s disease study

Evan Dewey and his family travel from Atlanta to participate in the ABATE study, a clinical trial evaluating a treatment that could reduce the likelihood of Alzheimer’s disease development in individuals with Down syndrome

May 30, 2024

Study to prevent Alzheimer’s disease in people with Down syndrome seeks participants

Participants may be able to join this study if they have Down syndrome, are between 35 and 50 years old and have a study partner willing to attend all study visits.

Paul Newhouse, MD, smiling in a white medical coat with a stethoscope and striped tie in a hospital corridor.
October 25, 2023

Vanderbilt Center for Cognitive Medicine named Alzheimer’s Clinical Trials Consortium Member Site

The Vanderbilt Center for Cognitive Medicine has been named an Alzheimer’s Clinical Trials Consortium Member Site.

Stylized side-profile illustration of a human head with the skull rendered translucent to reveal a network resembling brain blood vessels, dissolving into particles against a peach background.
September 30, 2021

Project seeks to treat Alzheimer’s in people with Down syndrome

A joint project between the Vanderbilt Kennedy Center and the Vanderbilt Center for Cognitive Medicine will help deliver Alzheimer’s disease therapies and treatments to people with Down syndrome (DS). 

Close-up of an upper arm with a small square translucent adhesive patch applied to the skin.
October 15, 2020

Study explores nicotine patch to treat late-life depression

Backed by nearly $5 million in funding, researchers from Vanderbilt University Medical Center are testing to see whether transdermal nicotine patches can improve mood, forgetfulness and attentiveness in adults over 60 with a diagnosis of depression.